SCHEMBL1134844

SCHEMBL1134844

CN(c1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.50
CES1 P23141 1/20 0.49
CHKA P35790 8/20 0.48
TSHR P16473 2/20 0.48
NR3C2 P08235 1/20 0.47
CSF1R P07333 1/20 0.46
CYP1A2 P05177 1/20 0.46
LMNA P02545 3/20 0.44
HPGD P15428 3/20 0.44
ALOX15 P16050 2/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 1/20 0.43
S1PR4 O95977 1/20 0.43
HSP90AA1 P07900 1/20 0.43
S1PR1 P21453 1/20 0.43
MAPK1 P28482 1/20 0.43
CCR6 P51684 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1134854 0.98 GSK3B (0.49) GSK3BCES1CHKATSHRNR3C2
SCHEMBL5213200 0.89 CHKA (0.55) CES1CHKATSHRLMNAHPGD
Hydrochloric Acid SCHEMBL6414496 0.87 CHKA (0.53) CES1CHKATSHRCSF1RLMNA
Ethane SCHEMBL6986774 0.87 CHKA (0.53) CES1CHKATSHRLMNAHPGD
SCHEMBL7155149 0.87 NR3C2 (0.56) GSK3BCES1CHKATSHRNR3C2
SCHEMBL20385081 0.84 MEN1 (0.52) GSK3BCES1CHKANR3C2LMNA
SCHEMBL31886 0.84 MEN1 (0.52) GSK3BCES1CHKANR3C2LMNA
SCHEMBL22931682 0.84 MEN1 (0.52) GSK3BCES1CHKANR3C2LMNA
SCHEMBL6567354 0.84 MEN1 (0.52) GSK3BCES1CHKANR3C2LMNA
Benzene SCHEMBL14537401 0.84 MEN1 (0.52) GSK3BCES1CHKANR3C2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350031-B2 Processes for the synthesis of levocetirizine and intermediates for use therein CIPLA LIMITED (IN) 2013-01-08 US claimed
CN-102046612-A Processes for the synthesis of levocetirizine and intermediates for use therein CIPLA LTD 2011-05-04 CN claimed
EP-2307392-A2 PROCESSES FOR THE SYNTHESIS OF LEVOCETIRIZINE AND INTERMEDIATES FOR USE THEREIN Cipla Limited (IN) 2011-04-13 EP claimed
WO-2009147389-A2 PROCESSES FOR THE SYNTHESIS OF LEVOCETIRIZINE AND INTERMEDIATES FOR USE THEREIN CIPLA LIMITED (IN) 2009-12-10 WO claimed
EP-1963296-A2 OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) 2008-09-03 EP claimed
WO-2007066163-A2 OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) 2007-06-14 WO claimed
CN-110294713-A A kind of preparation method of imidazoles methylamine like derivative 西华大学 2019-10-01 CN disclosed
CN-110294714-A Imidazoles methylamine like derivative and its synthetic method with indoles amine -2,3- dioxygenase (IDO) inhibitor activity 西华大学 2019-10-01 CN disclosed
CN-103613567-A Synthetic process for chlorcyclizine hydrochloride JIAOZUO FURUITANG PHARMACEUTICAL CO LTD 2014-03-05 CN disclosed
CN-102675017-A Method for preparing chiral diaryl- substitute methylamine HEBEI BRANT PHARMACEUTICAL CO LTD 2012-09-19 CN disclosed
WO-2012101475-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF ANTIHISTAMINIC DRUGS VIA A NOVEL CARBAMATE INTERMEDIATE JUBILANT LIFE SCIENCES LIMITED (IN) 2012-08-02 WO disclosed
US-20110251389-A1 Process For Making N-(Diphenylmethyl)piperazines ZHU JIE 2011-10-13 US disclosed
US-7989623-B2 Process for making n-(diphenylmethyl)piperazines SYNTHON BV (NL) 2011-08-02 US disclosed
US-7385058-B1 Triaminophosphine ligands for carbon-nitrogen and carbon-carbon bond formation IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2008-06-10 US disclosed
WO-2007066163-A2 OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) 2007-06-14 WO disclosed
EP-0355351-B1 Process for the preparation of amines BAYER AG (DE) 1993-11-10 EP disclosed
US-5011996-A Process for the preparation of amines BAYER AKTIENGESELLSCHAFT (DE) 1991-04-30 US disclosed
EP-0355351-A2 Process for the preparation of amines BAYER AG (DE) 1990-02-28 EP disclosed
US-4115413-A ACID FREE BAYER AKTIENGESELLSCHAFT (DE) 1978-09-19 US disclosed
US-4002631-A HEAT-SENSITIVE COLOR FORMERS HODOGAYA CHEMICAL CO., LTD. (JA) 1977-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251389-A1 Process For Making N-(Diphenylmethyl)piperazines CYP51A1, CYP3A5, CYP4Z1 GSK3B 2521/4885CES1 361/4885CHKA 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.